{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013816","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.638865+00:00","generated_at":"2026-05-15T08:18:22.674855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Imunon FY2025 net loss $14.5M; Phase 2 OS benefit 14.7 months","bullets":["Net loss for 2025 was $14.5M ($6.83/sh) vs $18.6M ($16.94/sh) in 2024; operating expenses down 23%.","Final Phase 2 OVATION 2 data show median OS improvement of 14.7 months (45.1 vs 30.4 months) with IMNN-001+SoC vs SoC alone.","Phase 3 OVATION 3 enrollment ahead of plan; first patient dosed in Q3 2025.","Cash and cash equivalents $8.8M as of Dec 31, 2025; $7M registered direct offering closed Dec 2025.","Strategic reorganization Feb 2026 to reduce expenses and focus on Phase 3 study."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013816","json":"https://secwatch.observer/filing/0001493152-26-013816.json","markdown":"https://secwatch.observer/filing/0001493152-26-013816.md","text":"https://secwatch.observer/filing/0001493152-26-013816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/0001493152-26-013816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:18:22.674855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8c73ba33df04f0521a7fe2beea40595f352f855","claim":"Imunon, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/0001493152-26-013816-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}